

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 September 2002 (12.09.2002)

PCT

(10) International Publication Number
WO 02/069884 A2031356 US PTO
10/764158

012304

(51) International Patent Classification⁷:

A61K

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US01/51090

(22) International Filing Date: 29 October 2001 (29.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/704,327 1 November 2000 (01.11.2000) US

(71) Applicant (for all designated States except US): ZEN-GEN, INC. [US/US]; 21800 Oxnard Street, Suite 980, Woodland Hills, CA 91367 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): LIPTON, James, M. [US/US]; 5800 Owensmouth Street #10, Woodland Hills, CA 91367 (US).

(74) Agent: Michael J. Wise; LYON & LYON LLP, 633 West Fifth Street, Suite 4700, Los Angeles, CA 90071-2066 (US).


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A SUNBURN TREATMENT AND SUNBURN PREVENTION METHOD



WO 02/069884 A2

embodiment of the invention, the one or more polypeptides are dissolved in a liquid that is associated with an absorbent material for application to sunburned skin.

(57) Abstract: The present invention is directed to a treatment for sunburn and a method for preventing sunburn. One aspect of this invention involves a sunburn treatment comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) for the treatment of the cutaneous inflammation caused by exposure to ultraviolet radiation. The polypeptides are at a level to effectively treat the cutaneous inflammation and are carried by a carrier. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above. In one preferred embodiment of the invention, the one or more polypeptides are used to prevent sunburn. In another preferred embodiment, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment, the carrier includes aloe vera and lidocaine hydrochloride. In another preferred

DESCRIPTIONA SUNBURN TREATMENT AND SUNBURN PREVENTION METHODField Of The Invention

5 The present invention relates to the field of preventing and treating sunburns.

Background Of The Invention

The skin is one of the largest body organs and functions as one of its major interfaces with the environment, including solar radiation. Exposure to solar radiation has the beneficial effects of stimulating the cutaneous synthesis of vitamin D and 10 providing radiant warmth. Foster, J., Sunburn, *eMedicine - Online Medical Reference Textbook*, (last modified May 1, 2000), <<http://emedicine.com/emerg/topic798.htm>>. Unfortunately, when the skin is subjected to excessive radiation in the ultraviolet range, deleterious effects, such as 15 sunburn, occur. Id. Sunburn is an acute cutaneous inflammatory reaction that follows excessive exposure of the skin to ultraviolet radiation (UVR). The inflammatory response occurs within 2-6 hours after exposure and peaks at 20-24 hours with symptoms such as erythema, warmth, tenderness, edema, and blistering (severe cases). Id.

Solar radiation is categorized along the electromagnetic spectrum that is 20 divided according to wavelength into ultraviolet (less than 400 nm), visible (400-760 nm) and infrared (greater than 760 nm). Bickers, D., Sun-Induced Disorders, *Emergency Medicine Clinics of North America*, 3(4): 659-663, 660 (1985). Ultraviolet radiation has been arbitrarily divided into three major components, the 25 UVA (320 to 400 nm); the UVB (290 to 320 nm); and the UVC (200 to 290nm). The UVC is completely absorbed by stratospheric ozone and does not reach the earth's surface. Id. UVB radiation is 1000 times more potent at inducing solar erythema than UVA and is, therefore, the principle cause of sunburn. Id. at 661. UVA comprises the majority of ultraviolet radiation that reaches the surface of the earth (about 90% at midday) and therefore accounts for a significant percentage of the acute

and chronic cutaneous effects of UVR. Foster, supra. Further, since the advent of tanning salons utilizing ultraviolet wavelengths in the UVA-spectrum, UVA-induced sunburn is becoming more common place. Cavello, J. and Deleo, V., Sunburn, *Dermatologic Clinics*, 4(2): 181-187, 181 (1986).

5 The minimal single dose of UVR required to produce erythema at an exposed site is known as the minimal erythema dose (MED). Moderate to severe sunburn occurs at 3-8 MEDs. Foster, supra. Irradiance, the rate of radiation delivery at the skin surface, and the duration of the irradiation also effect the sunburn response. The same magnitude of response is achieved by doubling the irradiance and halving the
10 irradiation period. This reciprocal relationship between intensity and time holds true for the delayed erythema response to UVR over a very wide range of times and irradiances up to 11 orders of magnitude. Fitzpatrick, et al., Acute Effects of Ultraviolet Radiation on the Skin: The Sunburn Reaction, *Dermatology in General Medicine*, 4th Edition, 1651-1655, 1651 (1993).

15 The precise biochemical pathways that lead to the sunburn reaction are not well understood, but appear to involve multiple inflammatory mediators, including histamine, prostaglandins and cytokines. Id. Histamine levels are elevated in suction blister fluid obtained during UVB- and UVA-induced erythema in humans, returning to normal after 24 hours although erythema is still prominent. Prostaglandin E₂
20 increased to approximately 150 percent of control levels after 24 hours and then diminished. Prostaglandins are known to evoke redness and pain in human skin after intradermal injection, and their presence in elevated amounts in suction blisters after UV irradiation suggests their involvement in sunburn erythema. Id. at 1654. UV irradiation is a potent stimulus for keratinocyte release of cytokines with local and
25 systemic proinflammatory and immunomodulatory actions. Id.

Erythema induced by UVA also is associated with histologic evidence of epidermal injury but this is much less pronounced than that which occurs after UVB. In the dermis, polymorphonuclear leukocytes and lymphocytes are seen in increased numbers. Endothelial cell enlargement also occurs. Bickers, supra, at 662.

Severity of sunburn is related to duration of exposure, skin type and amount of protection. Potts, Sunlight, Sunburn, and Sunscreens, *Postgrad. Med.*, 87:52-61 (1990). Factors influencing the cutaneous response to UVR depend on interactions among many other factors besides exposure time and dose. Wavelengths of the radiation source, skin characteristics such as pigmentation, hydration and skin thickness, and external factors such as wind, temperature and humidity all effect the response. Fitzpatrick, supra at 1652. Reflection off snow and sand may also lead to increased exposure. Foster, supra. Some medications are known to be sensitizing to ultraviolet radiation. Tricyclic antidepressants, antihistamines, anti-infectives, 5 antineoplastic agents, antipsychotic agents, diuretics, hypoglycemic agents, 10 nonsteroidal anti-inflammatory drugs, and sunscreens all may decrease an individual's tolerance for sun exposure. Potts, supra at 54.

Current treatment for sunburn includes the systemic administration of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) to inhibit the cyclooxygenase pathway and thereby reduce prostaglandin production. NSAIDs work best if administered within the first several hours after exposure. Bickers, supra at 663. Systemic corticosteroids are often employed and probably shorten the course of the pain that accompanies severe sunburn. Id. Corticosteroids should not be given to patients with severe, second-degree burns because they increase the risk of infection. 15 20 Foster, supra. Topical steroids show minimal, if any benefit. Id.

Over-the-counter topical remedies include anesthetics such as lidocaine hydrochloride, benzocaine, and pramoxine hydrochloride. Skin soothing ingredients such as aloe vera, tocopheryl acetate (Vitamin E), menthol, camphor, eucalyptus oil, and calamine are also popular ingredients known in the art.

25 Home topical remedies include taking a cool bath with oatmeal or baking soda; and spreading the juice of a cut potato, lavender essential oil, or chamomile on the burn. Mayhall, Ten Home Remedies for Sunburn, *Seasonal Health*, (July 14, 2000), <<http://drkoop.com/wellness/seasonal/summer/sunburn.html>>.

While these topical remedies may help soothe the skin or temporarily relieve the pain associated with sunburn, they are not a treatment for the underlying inflammation that defines sunburn. Non-steroidal anti-inflammatories must be given systemically soon after exposure to be effective. Moreover, patients with allergies to 5 NSAIDs, sensitive stomachs, or potential negative drug interactions may not be able to tolerate this treatment. Thus, a topical treatment that effectively reduces sunburn inflammation is needed.

Current sunburn prevention methods include wearing protective clothing and avoidance of the sun during midday. But these methods restrict the outdoor activities, 10 such as swimming, of a person wanting to avoid sunburn.

Topical products for the prevention of sunburn fall into two categories: physical barriers and chemical absorbers. Chemical sunscreens are generally aromatic compounds conjugated with a carbonyl group. After application, the chemical sunscreen components diffuse into the stratum corneum and adsorb or 15 conjugate with various proteins. Product effectiveness is determined by the depth of penetration, binding affinity for different proteins, and duration of protection. These chemicals absorb radiation in the UV spectrum. Potts, supra at 54. Chemical sunscreens have the disadvantages of possibly staining clothing and causing contact dermatitis. Id. Moreover, recently concerns have been raised regarding the 20 mutagenic properties of the most popular chemical sunscreens *p*-amino-benzoic acid (PABA) and PABA esters. Id.

Physical blockers, such as zinc oxide, talc, and titanium dioxide, reflect or scatter UVR. Many consumers find these products messy to apply and cosmetically unappealing. Id.

25 Thus, a sunburn prevention method that provides another option to avoid the painful inflammation of sunburn is needed.

Summary Of The Invention

The present invention is directed to a treatment for sunburn and a method for preventing sunburn. One aspect of this invention involves a sunburn treatment comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) for the treatment of the cutaneous inflammation caused by exposure to ultraviolet radiation. The polypeptides are at a level to effectively treat the cutaneous inflammation and are carried by a carrier. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above. In one preferred embodiment of the invention, the one or more polypeptides are used to prevent sunburn. In another preferred embodiment, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment, the carrier includes aloe vera and lidocaine hydrochloride and is used to treat sunburn. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a liquid that is associated with an absorbent material for application to sunburned skin.

Brief Description Of The Drawings

Figure 1 shows a representation of the chemical structure of one form of the KPV dimer for use with one aspect of the invention.

20 General Description Of The Invention

The references cited below are hereby incorporated by reference as if fully set forth herein. The present invention involves a treatment, methods of treatment and prevention, and a treatment packet for sunburn with the use of alpha-melanocyte stimulating hormone ("α-MSH") and/or its derivatives. α-MSH is an ancient thirteen amino-acid peptide (SEQ. ID. NO. 4) produced by post-translational processing of the larger precursor molecule propiomelanocortin. It shares the 1-13 amino acid sequence with adrenocorticotropic hormone ("ACTH"), also derived from propiomelanocortin. α-MSH is known to be secreted by many cell types including pituitary cells, monocytes, melanocytes, and keratinocytes. It can be found in the skin

of rats, in the human epidermis, or in the mucosal barrier of the gastrointestinal tract in intact and hypophysectomized rats. See e.g. Eberlie, A. N., *The Melanotrophins*, Karger, Basel, Switzerland (1998); Lipton, J.M., et. al., Anti-inflammatory Influence of the Neuroimmunomodulator α -MSH, *Immunol. Today* 18, 140-145 (1997); Thody, 5 A.J., et.al., MSH Peptides are Present in Mammalian Skin, *Peptides* 4, 813-815 (1983); Fox, J. A., et.al., Immunoreactive α -Melanocyte Stimulating Hormone, Its Distribution in the Gastrointestinal Tract of Intact and Hypophysectomized Rats, *Life. Sci.* 18, 2127-2132 (1981).

α -MSH and its derivatives are known to have potent antipyretic and anti-inflammatory properties, yet they have extremely low toxicity. They can reduce production of host cells' proinflammatory mediators *in vitro*, and can also reduce production of local and systemic reactions in animal models for inflammation. The "core" α -MSH sequence (4-10) (SEQ. ID. NO. 2), for example, has learning and memory behavioral effects but little antipyretic and anti-inflammatory activity. In 10 contrast, the active message sequence for the antipyretic and anti-inflammatory activities resides in the C-terminal amino-acid sequence of α -MSH, that is, lysine-proline-valine ("Lys-Pro-Val" or "KPV") (SEQ. ID. NO. 1). This tripeptide has activities *in vitro* and *in vivo* that parallel those of the parent molecule. The anti-inflammatory activity of α -MSH and/or its derivatives is disclosed in the following 15 20 25 30 patents are references which are hereby incorporated by reference: U.S. Patent No. 5,028,592, issued on July 2, 1991 to Lipton, J.M., entitled Antipyretic and Anti-inflammatory Lys Pro Val Compositions and Method of Use; U.S. Patent No. 5,157,023, issued on October 20, 1992 to Lipton, J.M., entitled Antipyretic and Anti-inflammatory Lys Pro Val Compositions and Method of Use; see also Catania, A., et. al., α -Melanocyte Stimulating Hormone in the Modulation of Host Reactions, *Endocr. Rev.* 14, 564-576 (1993); Lipton, J. M., et.al., Anti-inflammatory Influence of the Neuroimmunomodulator of α -MSH, *Immunol. Today* 18, 140-145 (1997); Rajora, N., et. al., α -MSH Production Receptors and Influence on Neopterin, in a Human Monocyte/macrophage Cell Line, *J. Leukoc. Biol.* 59, 248-253 (1996); Star, R.A., et. al., Evidence of Autocrine Modulation of Macrophage Nitric Oxide Synthase by α -

5 MSH, Proc. Nat'l. Acad. Sci. (USA) 92, 8015-8020 (1995); Lipton, J.M., et.al., Anti-inflammatory Effects of the Neuropeptide α -MSH in Acute Chronic and Systemic inflammation, Ann. N.Y. Acad. Sci. 741, 137-148 (1994); Fajora, N., et.al., α -MSH Modulates Local and Circulating tumor Necrosis Factor α in Experimental Brain Inflammation, J. Neuroosci, 17, 2181-2186 (1995); Richards, D.B., et. al., Effect of a-MSH (11-13) (lysine-proline-valine) on Fever in the Rabbit, Peptides 5, 815-817 (1984); Hiltz, M. E., et. al., Anti-inflammatory Activity of a COOH-terminal Fragment of the Neuropeptide α -MSH, FASEB J. 3, 2282-2284 (1989).

10 In a preferred embodiment of the invention, these anti-inflammatory activities are most particularly associated with the C-terminal amino-acid sequence – KPV. This tripeptide, along with α -MSH and its derivatives, are effective over a very broad range of concentrations, including picomolar concentrations that normally occur in human plasma.

15 As discussed in the background section, a topical treatment for sunburn is desired. For treatment of this condition, α -MSH and/or its derivatives can be applied locally to the site of the inflammation by methods known in the art. For example, α -MSH and/or its derivatives can be dissolved in solutions such as phosphate buffer saline, hyalurinate, methylcellulose, carboxymethylcellulose, or ethanol. Common carriers such as cream, ointment, balm, aerosol foam, aerosol spray, pump spray, gel, 20 stick, liquid, or absorbent material can carry α -MSH and/or its derivatives as active ingredients for treating sunburn. These carriers can be applied to the site of the inflammation by spray, absorbent material wipes, swabs, bandages, or fingers.

25 More specifically, the preferred embodiment of the invention is to dissolve α -MSH and/or its derivatives in a cream-based carrier. The cream containing the solvated α -MSH and/or its derivatives is then spread with fingers on the inflamed skin.

Another preferred embodiment of the invention is to dissolve α -MSH and/or its derivatives in a liquid-based carrier that also contains a skin soothing ingredient

and a topical anesthetic. Skin soothing ingredients include, but are not limited to, aloe vera, tocopheryl acetate, menthol, camphor, eucalyptus oil, calamine or any combination thereof. Topical anesthetics include, but are not limited to, lidocaine hydrochloride, benzocaine, pramoxine hydrochloride, or any combination thereof.

5 The carrier containing the solvated α -MSH and/or its derivatives may be stored in a pressurized canister with a spray top. Upon release of the carrier by a release valve or other mechanisms from the pressurized canister, an aerosol spray is formed. The user directs the spray to the inflamed area.

Another preferred embodiment of the invention is a treatment packet with a
10 wipe made of absorbent material that is treated with α -MSH and/or its derivatives that have been dissolved into a liquid-based carrier. The process for making wipes of absorbent material is well known in the art. For example, baby wipes, moist towelettes, make-up removal cloths, and alcohol swabs are all wipes of absorbent material. Commercial examples of such wipes include Chubs® Baby Soft Wipes,
15 Dexus® Antibacterial Hand Wipes, Dexus® Makeup Remover Wipes, Tinactin® Sports Wipes for Athlete's Foot, and B-D® Alcohol Swabs. Treatment of the wipe's absorbent material is accomplished by first soaking the absorbent material in a solution of α -MSH and/or its derivatives. The wipe remains in a liquid-impermeable packaging until use, when the package is opened and the wet wipe is applied to the
20 sunburned skin. The process for making liquid-impermeable packages are well known in the art. For example, packages made of layers of paper, metal foil, and metal foil coated paper are commonly used for packaging wipes of absorbent material. For example, moist towelettes, such as Massengill® Feminine Cleansing Soft Cloth Towelettes, and alcohol swabs, such as B-D® Alcohol Swabs, are
25 packaged in this manner.

Another preferred embodiment is a method of preventing sunburn by applying α -MSH and/or its derivatives that are carried by a cream, ointment, balm, aerosol foam, aerosol spray, pump spray, gel, stick, liquid, or absorbent material to skin exposed to the sun.

The following examples demonstrate the application of α -MSH and its derivatives to reduce sunburn inflammation.

One of skill in the art will be able to determine the appropriate dosage required for varying degrees of sunburn.

5 Example I

This example illustrates the biological functional equivalents of α -MSH and/or its derivatives.

Although specific amino acid sequences described here are effective, it is clear to those familiar with the art that amino acids can be substituted or deleted without altering the effectiveness of the peptides. Further, it is known that stabilization of the α -MSH sequence can greatly increase the activity of the peptide and that substitution of D-amino acid forms for L-forms can improve or decrease the effectiveness of the peptides. For example, a stable analog of α -MSH, [Nle⁴,D-Phe⁷]- α -MSH, which is known to have marked biological activity on melanocytes and melanoma cells, is approximately ten times more potent than the parent peptide in reducing fever. Further, adding amino acids to the C-terminal of α -MSH(11-13) (SEQ. ID. NO. 1) sequence can reduce or enhance antipyretic potency. Addition of glycine to form the 10-13 sequence (SEQ. ID. NO. 5) slightly decreased potency; the 9-13 sequence (SEQ. ID. NO. 6) was almost devoid of activity, whereas the potency of the 8-13 sequence (SEQ. ID. NO. 7) was greater than that of the 11-13 sequence (SEQ. ID. NO. 1). It is known that Ac-[D-K11]- α -MSH 11-13-NH₂ has the same general potency as the L-form of the tripeptide α -MSH (11-13) (SEQ. ID. NO. 1). However, substitution with D-proline in position 12 of the tripeptide rendered it inactive. see e.g. Holdeman, M., et. al., Antipyretic Activity of a Potent α -MSH Analog, Peptides 6, 273-5 (1985). Deeter, L.B., et. al., Antipyretic Properties of Centrally Administered α -MSH Fragments in the Rabbit, Peptides 9, 1285-8 (1989). Hiltz, M.E., Anti-inflammatory Activity of α -MSH (11-13) Analogs: Influences of Alterations in Stereochemistry, Peptides 12, 767-71 (1991).

Biological functional equivalents can also be obtained by substitution of amino acids having similar hydropathic values. Thus, for example, isoleucine and leucine, which have a hydropathic index +4.5 and +3.8, respectively, can be substituted for valine, which has a hydropathic index of +4.2, and still obtain a protein 5 having like biological activity. Alternatively, at the other end of the scale, lysine (-3.9) can be substituted for arginine (-4.5), and so on. In general, it is believed that amino acids can be successfully substituted where such amino acid has a hydropathic score of within about +/- 1 hydropathic index unit of the replaced amino acid.

Furthermore, these modified analogs of α -MSH and/or its derivatives can also 10 form dimers as exemplified by the KPV dimer in Figure 1.

Example II

A person spends time in the sun with exposed skin. Within hours, red and painful inflammation appears on the exposed area. An examination by a physician 15 determines that the patient has sunburn from over-exposure to ultraviolet radiation. Treatment can include topical application of pharmacologically effective amounts of α -MSH and/or its derivatives carried in a cream, an ointment, a balm, an aerosol foam, an aerosol spray, a pump spray, a gel, a stick, a liquid, or the absorbent material of a wipe. The topical treatment can be applied once or multiple times according to 20 the discretion of the physician until the inflammation is resolved.

Example III

A person plans on spending time in the sun with exposed skin and desires to prevent sunburn. Prior to exposure, the person topically applies a pharmacologically 25 effective amount of α -MSH and/or its derivatives carried in a cream, an ointment, a balm, an aerosol foam, an aerosol spray, a pump spray, a gel, a stick, a liquid, or the absorbent material of a wipe. The topical treatment can be re-applied once or

multiple times as necessary to prevent sunburn, especially after towel drying, swimming, or perspiring.

Example IV

5 Some sample formulations include combining α -MSH and/or its derivatives in

a:

- a. Cream formulation also containing water, glycerin, mineral oil, lanolin, stearic acid, cetyl alcohol, aloe vera, coconut oil, tocopheryl acetate, fragrance, and coloring;
- 10 b. Cream formulation also containing water, stearic acid, camphor, menthol, and eucalyptus oil;
- c. Ointment also containing aloe vera, petrolatum, and mineral oil;
- d. Pump Spray also containing lidocaine HCl, water, aloe vera, glycerin, fragrance, and coloring;
- 15 e. Aerosol Spray also containing lidocaine HCl, aloe vera, isobutane, and cetyl acetate;
- f. Gel formulation also containing lidocaine HCl, water, aloe vera, glycerin, fragrance, and coloring; and a
- 20 g. Foam formulation also containing water, isobutane, stearic acid, aloe vera, tocopherol acetate, fragrance and coloring.

It will be understood by one skilled in the art that other inactive ingredients can be combined with the above formulations.

The preceding examples demonstrate the application of α -MSH and/or its derivatives to reduce and prevent sunburn inflammation. These are only examples and are not intended to limit the invention to these examples. It is understood that modifying the examples above does not depart from the spirit of the invention. It is further understood that the examples can be applied on its own or in combination with each other.

Claims:

1. A sunburn treatment comprising:
 - a carrier to be applied to cutaneous inflammation caused by exposure to ultraviolet radiation;
 - 5 at least one polypeptide including an amino acid sequence selected from a group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing;
 - 10 wherein the at least one polypeptide is at a level to effectively treat the cutaneous inflammation; and
 - wherein the carrier carries the at least one polypeptide.
2. The sunburn treatment of claim 1 wherein the at least one polypeptide includes a dimer formed from any amino acid sequence in the group in claim 1.
3. The sunburn treatment of claim 2 wherein the dimer is a KPV dimer.
- 15 4. The sunburn treatment of claim 1 wherein the amino acid sequence KPV (SEQ. ID. NO. 1), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) is located at the C-terminal of the at least one polypeptide.
5. The sunburn treatment of claim 1 wherein the amino acid sequence KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 20 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), includes at least one amino acid in the D-form.
6. The sunburn treatment of claim 1 wherein the at least one polypeptide is N-acetylated or C-amidated or both.

7. The sunburn treatment of claim 1 wherein the carrier is a cream, an ointment, a balm, an aerosol foam, an aerosol spray, a pump spray, a gel, a stick, or a liquid.

8. The sunburn treatment of claim 7 wherein the carrier includes a skin 5 soothing ingredient.

9. The sunburn treatment of claim 8 wherein the skin soothing ingredient is aloe vera, tocopheryl acetate, menthol, camphor, eucalyptus oil, calamine or any combination thereof.

10. The sunburn treatment of claim 8 wherein the skin soothing ingredient 10 is aloe vera.

11. The sunburn treatment of claim 9 wherein the carrier further includes a topical anesthetic.

12. The sunburn treatment of claim 11 wherein the topical anesthetic is lidocaine hydrochloride.

15 13. The sunburn treatment of claim 7 wherein the carrier includes a topical anesthetic.

14. The sunburn treatment of claim 13 wherein the topical anesthetic is selected from the group consisting of lidocaine hydrochloride, benzocaine, pramoxine hydrochloride, or any combination thereof.

20 15. The sunburn treatment of claim 13 wherein the topical anesthetic is lidocaine hydrochloride.

16. The sunburn treatment of claim 14 wherein the carrier further includes a skin soothing ingredient.

17. The sunburn treatment of claim 16 wherein the skin soothing ingredient is aloe vera.

5 18. The sunburn treatment of claim 7 wherein the carrier includes a skin soothing ingredient and a topical anesthetic.

19. The sunburn treatment of claim 7 wherein the carrier includes a skin soothing ingredient that is aloe vera, tocopheryl acetate, menthol, camphor, eucalyptus oil, calamine or any combination thereof; and
10 a topical anesthetic that is lidocaine hydrochloride, benzocaine, pramoxine hydrochloride, or any combination thereof.

20. The sunburn treatment of claim 7 wherein the carrier includes aloe vera and lidocaine hydrochloride.

21. A sunburn treatment kit comprising:
15 a liquid impermeable packaging;
an absorbent material;
a carrier for application to cutaneous inflammation caused by exposure to ultraviolet radiation;
at least one polypeptide including an amino acid sequence selected
20 from a group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing;
wherein the at least one polypeptide is at a level to effectively treat the cutaneous inflammation;
25 wherein the carrier carries the at least one polypeptide; and

wherein the carrier is applied to the cutaneous inflammation by the absorbent material.

22. The sunburn treatment kit of claim 21 wherein the at least one polypeptide includes a dimer formed from any amino acid sequence in the group in
5 claim 21.

23. The sunburn treatment kit of claim 22 wherein the dimer is a KPV dimer.

24. The sunburn treatment kit of claim 21 wherein the amino acid sequence KPV (SEQ. ID. NO. 1), HFRWGKPV (SEQ. ID. NO. 3), or
10 SYSMEHFRWGKPV (SEQ. ID. NO. 4) is located at the C-terminal of the at least one polypeptide.

25. The sunburn treatment kit of claim 21 wherein the amino acid sequence KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), includes at least one
15 amino acid in the D-form.

26. The sunburn treatment kit of claim 21 wherein the at least one polypeptide is N-acetylated or C-amidated or both.

27. The sunburn treatment kit of claim 21 wherein the carrier is a cream, an ointment, a balm, a gel, or a liquid.

20 28. The sunburn treatment kit of claim 27 wherein the carrier includes a skin soothing ingredient.

29. The sunburn treatment kit of claim 28 wherein the skin soothing ingredient is aloe vera, tocopheryl acetate, menthol, camphor, eucalyptus oil, calamine or any combination thereof.

30. The sunburn treatment kit of claim 28 wherein the skin soothing 5 ingredient is aloe vera.

31. The sunburn treatment kit of claim 29 wherein the carrier further includes a topical anesthetic.

32. The sunburn treatment kit of claim 31 wherein the topical anesthetic is lidocaine hydrochloride.

10 33. The sunburn treatment kit of claim 27 wherein the carrier includes a topical anesthetic.

34. The sunburn treatment kit of claim 33 wherein the topical anesthetic is lidocaine hydrochloride, benzocaine, pramoxine hydrochloride, or any combination thereof.

15 35. The sunburn treatment kit of claim 33 wherein the topical anesthetic is lidocaine hydrochloride.

36. The sunburn treatment kit of claim 34 wherein the carrier further includes a skin soothing ingredient.

37. The sunburn treatment kit of claim 34 wherein the skin soothing 20 ingredient is aloe vera.

38. The sunburn treatment kit of claim 27 wherein the carrier includes a skin soothing ingredient and a topical anesthetic.

39. The sunburn treatment kit of claim 27 wherein the carrier includes a skin soothing ingredient that is aloe vera, tocopheryl acetate, 5 menthol, camphor, eucalyptus oil, calamine or any combination thereof; and a topical anesthetic that is lidocaine hydrochloride, benzocaine, pramoxine hydrochloride, or any combination thereof.

40. The sunburn treatment kit of claim 27 wherein the carrier includes aloe vera and lidocaine hydrochloride.

10 41. A method of treating sunburn comprising:
applying a carrier to cutaneous inflammation caused by exposure to
ultraviolet radiation;
using at least one polypeptide including an amino acid sequence
selected from the group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID.
15 NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or
a biologically functional equivalent of any of the foregoing;
wherein the at least one polypeptide is at a level to effectively treat the
cutaneous inflammation; and
wherein the carrier carries the at least one polypeptide.

20 42. The method of claim 41 wherein the at least one polypeptide includes a dimer formed from any amino acid sequence in the group in claim 41.

43. The method of claim 42 wherein the dimer is a KPV dimer.

44. The method of claim 41 wherein the amino acid sequence KPV (SEQ. ID. NO. 1), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) is located at the C-terminal of the at least one polypeptide.

45. The method of claim 41 wherein the amino acid sequence KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), includes at least one amino acid in the D-form.

46. The method of claim 41 wherein the at least one polypeptide is N-acetylated or C-amidated or both.

10 47. The method of claim 41 wherein the carrier is a cream, an ointment, a balm, an aerosol foam, an aerosol spray, a pump spray, a gel, a stick, or a liquid.

48. The method of claim 47 wherein the carrier contains a skin soothing ingredient.

15 49. The method of claim 48 wherein the skin soothing ingredient is aloe vera, tocopheryl acetate, menthol, camphor, eucalyptus oil, calamine, or any combination thereof.

50. The method of claim 48 wherein the skin soothing ingredient is aloe vera.

20 51. The method of claim 49 wherein the carrier further includes a topical anesthetic.

52. The method of claim 51 wherein the topical anesthetic is lidocaine hydrochloride.

53. The method of claim 47 wherein the carrier contains a topical anesthetic.

54. The method of claim 53 wherein the topical anesthetic is lidocaine hydrochloride, benzocaine, pramoxine hydrochloride or any combination thereof.

5 55. The method of claim 53 wherein the topical anesthetic is lidocaine hydrochloride.

56. The method of claim 54 wherein the carrier further includes a skin soothing ingredient.

10 57. The method of claim 56 wherein the skin soothing ingredient is aloe vera.

58. The method of claim 47 wherein the carrier contains a skin soothing ingredient and a topical anesthetic.

15 59. The method of claim 47 wherein the carrier includes a skin soothing ingredient that is aloe vera, tocopheryl acetate, menthol, camphor, eucalyptus oil, calamine or any combination thereof; and a topical anesthetic that is lidocaine hydrochloride, benzocaine, pramoxine hydrochloride, or any combination thereof.

60. The method of claim 47 wherein the carrier contains aloe vera and lidocaine hydrochloride.

20 61. A method of preventing sunburn comprising: applying a carrier to skin to be exposed to ultraviolet radiation;

using at least one polypeptide including an amino acid sequence selected from the group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing;

5 wherein the at least one polypeptide is at a level to effectively prevent cutaneous inflammation due to exposure to ultraviolet radiation; and
 wherein the carrier carries the at least one polypeptide.

62. The method of claim 61 wherein the at least one polypeptide includes a dimer formed from any amino acid sequence in the group in claim 61.

10 63. The method of claim 62 wherein the dimer is a KPV dimer.

64. The method of claim 61 wherein the amino acid sequence KPV (SEQ. ID. NO. 1), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) is located at the C-terminal of the at least one polypeptide.

15 65. The method of claim 61 wherein the amino acid sequence KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), includes at least one amino acid in the D-form.

66. The method of claim 61 wherein the at least one polypeptide is N-acetylated or C-amidated or both.

20 67. The method of claim 61 wherein the carrier is a cream, an ointment, a balm, an aerosol foam.

THIS PAGE BLANK (USPTO)




Fig. 1

THIS PAGE BLANK (USPTO)